Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21084775 | 0.88 | PAX8 (0.46) | MEN1KMT2ARAB9APAX8BRD4 | |
| SCHEMBL12117478 | 0.81 | LIPE (0.43) | PAX8BRD4ALDH1A1TP53MAPT | |
| SCHEMBL15221617 | 0.81 | TSHR (0.43) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL27594895 | 0.81 | MEN1 (0.40) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL13311040 | 0.80 | PAX8 (0.41) | MEN1KMT2ARAB9APAX8BRD4 | |
| SCHEMBL29837226 | 0.80 | PAX8 (0.41) | MEN1KMT2ARAB9APAX8BRD4 | |
| SCHEMBL30568129 | 0.80 | PAX8 (0.41) | MEN1KMT2ARAB9APAX8BRD4 | |
| SCHEMBL1847986 | 0.80 | MEN1 (0.39) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL16389414 | 0.80 | GSK3B (0.41) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL29004738 | 0.79 | GBA1 (0.45) | MEN1KMT2ARAB9AHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6909001-B2 | Method of making tricyclic aminocyanopyridine compounds | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040127714-A1 | Method of making tricyclic aminocyanopyridine compounds | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-1086076-A1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065870-A2 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | MEN1 2597/4885KMT2A 658/4885RAB9A 1999/4885 |
| US-20040127714-A1 | Method of making tricyclic aminocyanopyridine compounds | MAP4K2, PACSIN2, MAPKAPK2 | MEN1 2947/4885KMT2A 1232/4885RAB9A 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.